SuperSonic Imagine to Feature its Non-Invasive, 60-Second Liver Exam at The Liver Meeting 2016 - Seite 2

Oranit Cohen-Ezra et al.

Probiotics do not improve hepatic outcomes after Laparoscopic Sleeve Gastrectomy surgery: a randomized clinical trial (Abstract 1123)
Shiri Sherf Dagan et al.

Sunday, November 13

2-dimensional shear wave elastography rather than HVPG significantly improves MELD-Na to predict survival in decompensated cirrhosis patients (Abstract 1406)
Maja Thiele et al.

"SuperSonic Imagine's dedication to advancing the evaluation of chronic liver disease has enabled us to develop innovative solutions such as image-guided ShearWave Elastography, an accurate, easy-to-use and pain-free liver exam," explained SuperSonic Imagine Founder and Chief Innovation Officer Jacques Souquet. "We are excited to share this technology's capabilities at The Liver Meeting, where we know hepatologists from around the world will share our enthusiasm for the non-invasive quantification of liver stiffness."

SSI will be exhibiting at booth #313 throughout The Liver Meeting.

The Liver Meeting® is a registered trademark of the American Association for the Study of Liver Diseases.

About SuperSonic Imagine

Founded in 2005 and based in Aix-en-Provence (France), SuperSonic Imagine is a company specializing in medical imaging. The company designs, develops and markets a revolutionary ultrasound system, Aixplorer®, with an UltraFast™ platform that can acquire images 200 times faster than conventional ultrasound systems. In addition to providing exceptional image quality, this unique technology is the foundation of several innovations which have changed the paradigm of ultrasound imaging: ShearWave™ Elastography (SWE™), UltraFast™ Doppler and more recently Angio PL.U.S* - Planewave UltraSensitive™ Imaging.

ShearWave Elastography allows physicians to visualize and analyze the stiffness of tissue in a real-time, reliable, reproducible and non-invasive manner. This criteria has become an important parameter in diagnosing potentially malignant tissue or other diseased tissue. As of today, over 300 peer-reviewed publications have demonstrated the value of SWE for the clinical management of patients with a wide range of diseases. UltraFast Doppler combines Color Flow Imaging and Pulsed Wave Doppler into one simple exam, providing physicians with exam results simultaneously and helping to increase patient throughput. The latest innovation, Angio PL.U.S, provides a new level of microvascular imaging through significantly improved color sensitivity and spatial resolution while maintaining exceptional 2D imaging.

SuperSonic Imagine has been granted regulatory clearances for the commercialization of Aixplorer in key global markets. SuperSonic Imagine is a listed company since April 2014 on the Euronext, symbol SSI. For more information about SuperSonic Imagine, please go to www.supersonicimagine.com.

*Pending FDA 510(k) clearance

Contact information:

SuperSonic Imagine
Bernard Doorenbos
CEO
Email Contact
[phone]

SuperSonic Imagine
Marketing & Communication
Emmanuelle Vella
Email Contact
[phone]

NewCap
Investor Relations - EU
Pierre Laurent / Florent Alba
Email Contact
[phone]

Pascale Communication
Media Relations - US
Amy Phillips
Email Contact
[phone]